Still ‘Work To Be Done’ After Ranibizumab Approval, Says Samsung Bioepis
Executive Kyung-Ah Kim Sees Opportunity To Lead On Ophthalmic Biosimilars
Samsung Bioepis recently broke new ground with the first US approval for a biosimilar with ophthalmic indications. But, senior vice-president and development division leader Kyung-Ah Kim tells Generics Bulletin, there remains work to be done to ensure that ophthalmic biosimilars can meet their full potential.
